Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | carbonic anhydrase II | Starlite/ChEMBL | References |
Candida albicans | Involved in protection against oxidative damage | Starlite/ChEMBL | References |
Homo sapiens | carbonic anhydrase I | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | Carbonic anhydrase like protein 2 precursor | carbonic anhydrase II | 260 aa | 259 aa | 32.0 % |
Trypanosoma brucei | carbonic anhydrase-like protein | carbonic anhydrase I | 261 aa | 281 aa | 25.3 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium tuberculosis | Beta-carbonic anhydrase CanB | 0.0156 | 0 | 0.5 |
Brugia malayi | Eukaryotic-type carbonic anhydrase family protein | 0.0181 | 0.2058 | 0.5 |
Loa Loa (eye worm) | eukaryotic-type carbonic anhydrase | 0.0181 | 0.2058 | 0.5 |
Mycobacterium leprae | CARBONIC ANHYDRASE (CARBONATE DEHYDRATASE) (CARBONIC DEHYDRATASE) | 0.0275 | 1 | 0.5 |
Loa Loa (eye worm) | carbonic anhydrase 3 | 0.0181 | 0.2058 | 0.5 |
Echinococcus granulosus | carbonic anhydrase II | 0.0181 | 0.2058 | 0.5 |
Echinococcus multilocularis | carbonic anhydrase II | 0.0181 | 0.2058 | 0.5 |
Leishmania major | carbonic anhydrase family protein, putative | 0.0275 | 1 | 1 |
Mycobacterium ulcerans | carbonic anhydrase | 0.0275 | 1 | 0.5 |
Brugia malayi | Putative carbonic anhydrase 5 precursor | 0.0181 | 0.2058 | 0.5 |
Trypanosoma cruzi | carbonic anhydrase-like protein, putative | 0.0181 | 0.2058 | 0.5 |
Trypanosoma brucei | carbonic anhydrase-like protein | 0.0181 | 0.2058 | 0.5 |
Trypanosoma cruzi | carbonic anhydrase-like protein, putative | 0.0181 | 0.2058 | 0.5 |
Schistosoma mansoni | carbonic anhydrase | 0.0275 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Kd (binding) | = 2000 nM | Binding affinity to human CA2 in presence of sodium sulfate and ANS at pH 7.5 by ThermoFluor assay | ChEMBL. | 16759092 |
Kd (binding) | = 2000 nM | Binding affinity to human CA2 in presence of sodium sulfate and ANS at pH 7.5 by ThermoFluor assay | ChEMBL. | 16759092 |
Kd (binding) | = 3750 nM | Binding affinity to human CA2 at pH 7.4 by ThermoFluor assay | ChEMBL. | 16759092 |
Kd (binding) | = 3750 nM | Binding affinity to human CA2 at pH 7.4 by ThermoFluor assay | ChEMBL. | 16759092 |
Kd (binding) | = 4550 nM | Binding affinity to human CA2 by ThermoFluor assay | ChEMBL. | 16759092 |
Kd (binding) | = 4550 nM | Binding affinity to human CA2 by ThermoFluor assay | ChEMBL. | 16759092 |
Ki (binding) | = 12 nM | Inhibitory activity against human cloned isoenzyme carbonic anhydrase II (hCA II), by esterase method. | ChEMBL. | 12617903 |
Ki (binding) | = 12 nM | Inhibitory activity against human cloned isoenzyme carbonic anhydrase II (hCA II), by esterase method. | ChEMBL. | 12617903 |
Ki (binding) | = 13 nM | Inhibitory activity against human cloned isoenzyme carbonic anhydrase I (hCA I), by esterase method. | ChEMBL. | 12617903 |
Ki (binding) | = 13 nM | Inhibitory activity against human cloned isoenzyme carbonic anhydrase I (hCA I), by esterase method. | ChEMBL. | 12617903 |
Ki (binding) | = 13 nM | Inhibition of human carbonic anhydrase 2 preincubated for 15 mins measured for 10 to 100 sec by stopped-flow method | ChEMBL. | 22424239 |
Ki (binding) | = 1913 nM | Inhibition of Candida albicans CaNce103 preincubated for 15 mins measured for 10 to 100 sec by stopped-flow method | ChEMBL. | 22424239 |
Ki (binding) | = 7960 nM | Inhibition of human CA2 by carbon dioxide hydration | ChEMBL. | 16759092 |
Ki (binding) | = 7960 nM | Inhibition of human CA2 by carbon dioxide hydration | ChEMBL. | 16759092 |
Ki (binding) | = 8020 nM | Inhibition of human CA2 by 4-nitrophenyl acetate hydrolysis | ChEMBL. | 16759092 |
Ki (binding) | = 8020 nM | Inhibition of human CA2 by 4-nitrophenyl acetate hydrolysis | ChEMBL. | 16759092 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
3 literature references were collected for this gene.